Boundless Bio Launches to Deliver Transformative Therapies to Patients with Diff
$46 Million Series A Round Co-led by ARCH Venture Partners and City Hill Ventures Company is Developing a Novel Class of Cancer Therapeutics Based on a Biology Platform that Leverages World-Class Scientific Founders’ Pioneering Discoveries about the Role of Extrachromosomal DNA (ecDNA) in Driving Aggressive Cancers
More ›